Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 793-802

  Vlodavsky, Israel ^a   Friedmann, Yael ^a   Elkin, Michael ^a   Aingorn, Helena ^a   Atzmon, Ruth ^a   Ishai Michaeli, Rivka ^a   Bitan, Menachem ^a   Pappo, Orit ^a   Peretz, Tuvia ^b   Michal, Israel ^b   Spector, Larissa ^b   Pecker, Iris ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Rabin Science Park   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE;

AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOCYTOCHEMISTRY; LUNG METASTASIS; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 4; CLONING, MOLECULAR; DISEASE PROGRESSION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; GENOMIC LIBRARY; GLUCURONIDASE; GLYCOSIDE HYDROLASES; HUMANS; LIVER NEOPLASMS; MAMMALS; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MOTHS; NEOPLASM METASTASIS; PLACENTA; PREGNANCY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

INSECTA; MAMMALIA; MURINAE;

EID: 0033057962     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10518     Document Type: Article

References (50)

1. Kjellen, L. & Lindahl, U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443-475 (1991).
2. David, G. Integral membrane heparan sulfate proteoglycan. FASEB J. 7, 1023-1030 (1993).
3. Jackson, R.L., Busch, S.J. & Cardin, A.L. Glycosaminoglycans: Molecular properties, protein interactions and role in physiological processes. Physiol. Rev. 71, 481-539 (1991).
4. Wight, T.N., Kinsella, M.G. & Qwarnstromn, E.E. The role of proteoglycans in cell adhesion, migration and proliferation. Curr. Opin. Cell Biol. 4, 793-801 (1992).
5. Rapraeger, A.C. Trie coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr. Opin. Cell Biol. 5, 844-853 (1993).
6. Wight, T.N. Cell biology of arterial proteoglycans. Arteriosclerosis 9, 1-20 (1989).
7. Vlodavsky, I., Fuks, Z., Bar-Ner, M., Ariav, Y. & Schirrmacher, V. Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res. 43, 2704-2711 (1983).
8. Nakajima, M., Irimura, T., DiFerrante, D., DiFerrante, N. & Nicholson, G.L. Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B16 melanoma sublines. Science 220, 611-613 (1983).
9. Nakajima, M., Irimura, T. & Nicolson, G.L. Heparanase and tumor metastasis. J. Cell. Biochem. 36, 157-167 (1988).
10. Vlodavsky, I. et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14, 290-302 (1995).
11. Parish, C.R., Coombe, D.R., Jakobsen, K.B. & Underwood, P.A. Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor cell-derived heparanase. Int. J. Cancer 40, 511-517 (1987).
12. Lider, O. et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with heparinoid inhibitors of T lymphocyte heparanase. J. Clin. Invest. 83, 752-756 (1989).
13. Willenborg, D. O. & Parish, C. R. Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. J. Immunol. 140, 3401-3405 (1988).
14. Vlodavsky, I. et al. Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112-127 (1992).
15. Graham, L.D. & Underwood, P.A. Comparison of the heparanase enzymes from mouse melanoma cells, mouse macrophages and human platelets. Biochem. Mol. Biol. 39, 563-571 (1996).
16. Ishai-Michaeli, R., Elder, A. & Vlodavsky, I. Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Reg. 1, 833-842 (1990).
17. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P. & Fuks, Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem. Sci. 16, 268-271 (1991).
18. Eisenberg, S., Sehayek, E., Olivecrona, T. & Vlodavsky, I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J. Clin. Invest. 90, 2013-2021 (1992).
19. Oosta, G.M., Favreau, L.V., Beeler, D.L. & Rosenberg, R.D. Purification and properties of human platelet heparitinase. J. Biol. Chem. 257, 11249-11255 (1982).
20. Freeman, C. & Parish, C.R. Human platelet heparanase: Purification, characterization and catalytic activity. Biochem. J. 330, 1341-1350 (1998).
21. Hoogewerf, A.J. et al. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J. Biol. Chem. 270, 3268-3277 (1995).
22. Gonzalo, V. et al. Partial sequence of human platelet heparitinase and evidence of its ability to polymerize. Biochim. Biophys. Acta 1429, 431-438 (1999).
23. Jin, L., Nakajima, M. & Nicolson, G.L. Immunochemical localization of heparanase in mouse and human melanoma. Int. J. Concer 45, 1088-1095 (1990).
24. De Vouge, M.W. et al. Immunoselection of GRP94/Endoplasmin from a KNRK cell specific g gt11 library using antibodies directed against a putative heparanase amino-terminal peptide. Int. J. Cancer 56, 286-294 (1994).
25. Goshen, R. et al. Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. Mol. Hum. Reprod. 2, 679-684 (1996).
26. Bar-Ner, M., Eldor, A., Wasserman, L., Matzner, Y. & Vlodavsky, I. Inhibition of heparanase mediated degradation of extracellular matrix heparan sulfate by modified and non-anticoagulant heparin species. Blood 70, 551-557 (1987).
27. Even-Ram, S. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med. 8, 909-914 (1998).
28. Larizza, L., Schirrmacher, V. & Pfluger, E. Acquisition of high metastatic capacity after in vitro fusion of a non-metastatic tumor line with a bone marrow derived macrophage. J. Exp. Med. 160, 1579-1584 (1984).
29. Klein, U. & Figura, K.V. Substrate specificity of a heparan-sulfate degrading endoglucuronidase from human placenta. Hoppe-Seyler's Z Physiol. Chem. 360, 1465-1471 (1979).
30. Bame, K. J., & Robson K. Heparanases produce distinct populations of heparan sulfate glycosaminoglycans in Chinese hamster ovary cells. J. Biol. Chem. 272, 2245-2251 (1997).
31. Sandback-Pikas, D., Li, J-P., Vlodavsky, I. & Lindahl, U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273, 18770-18777 (1998).
32. Pillarisetti, S. et al. Endothelial cell heparanase modulation of lipoprotein lipase activity. J. Biol. Chem. 272, 15753-15759 (1997).
33. Yahalom, J., Eldor, A., Fuks, Z. & Vlodavsky, I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J. Clin. Invest. 74, 1842-1849 (1984).
34. Bashkin, P., Razin, E., Eldor, A. & Vlodavsky, I. Degranulating mast cells secrete an endoglycosidase which degrades heparan sulfate in subendothelial extracellular matrix. Blood 75, 2204-2212 (1990).
35. Matzner, Y. et al. Degradation of heparan sulfate in the subendothelial basement membrane by a readily released heparanase from human neutrophils. J. Clin. Invest. 76, 1306-1313 (1985).
36. Naparstek, Y., Cohen, I.R., Fuks, Z. & Vlodavsky, I. Activated T lymphocytes produce a matrix-degrading heparan sulfate endoglycosidase. Nature 310, 241-243 (1984).
37. Peretz, T. et al. Maintenance on extracellular matrix and expression of heparanase activity by human ovarian carcinoma cells from biopsy specimens. Int. J. Cancer 45, 1054-1060 (1990).
38. Kleiner, D. E. & Stetler-Stevenson, W. G. Structural biochemstry and activation of matrix metalloproteases. Curr. Opin. Cell Biol. 5, 891-897 (1993).
39. Stetler-Stevenson, W. G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9, 289-303 (1990).
40. Mignatti, P. & Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195 (1993).
41. Bar-Ner, M. et al. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells. Int. J. Cancer 35, 483-491 (1985).
42. Vlodavsky, I. et al. in Tumor Angiogenesis (eds. Lewis, C.E., Bicknell, R &Ferrara, N.) 125-140 (Oxford University Press, Oxford, UK, 1997).
43. Vlodavsky, I., Bar-Shavit, R., Korner, G. & Fuks, Z. in Basement Membranes: Cellular and Molecular Aspects (eds. Rohrbach, D.H. & Timpl, R.) 327-343 (Academic, Orlando, Florida, 1993).
44. Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P. & Ornitz, D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841-848 (1991).
45. Miao, H-Q., Ornitz, D. M., Eingorn, E., Ben-Sasson, S. A. & Vlodavsky I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J. Clin. Invest. 99, 1565-1575 (1997).
46. Vlodavsky, I. et al. Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA 84, 2292-2296 (1987).
47. Vlodavsky, I. & Christofori, G. in Antiangiogenic Agents in Cancer Therapy (ed. Teicher, B.A.) 93-118 (Humana, Totowa, New Jersey, 1998).
48. Soule, H.D. et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50, 6075-6086 (1990).
49. Vlodavsky, I. in Current protocols in Cell Biology, Vol. I, Suppl. I (eds. Bonifacino, J.S., Dasso, M, Harford, J.B, Lippincott-Schwartz, J & Yamada, K.M.) 10.4.1-10.4.14 (John Wiley & Sons, New York, New York, 1999).
50. Savitsky, K. et al. Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-translational regulation of ATM gene expression. Nucleic Acids Res. 25, 1678-1684 (1997).